Liverpool HEP Interactions

Based on drug interaction studies conducted with Epclusa, no clinically significant drug interactions have been observed with dolutegravir. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007, velpatasvir or dolutegravir was observed.
Based on drug interaction studies conducted with Epclusa, no clinically significant drug interactions have been observed with the combination of emtricitabine, rilpivirine, and tenofovir DF. Coadministration of rilpivirine (25 mg once daily with emtricitabine and tenofovir-DF) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Rilpivirine Cmax, AUC and Cmin decreased by 7%, 5% and 4%, respectively. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed with the combination of emtricitabine, rilpivirine, and tenofovir DF.

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) with rilpivirine/emtricitabine/tenofovir-DF (200/25/300 mg, once daily) was studied in 24 healthy volunteers. Sofosbuvir AUC and Cmax increased by 16% and 9%, respectively. GS-331007 AUC and Ctau increased by 4% and 12%, while Cmax decreased by 4%. Velpatasvir AUC and Cmax decreased by 1% and 6%, while Ctau increased by 2%. No dosage adjustments are required.
Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) with dolutegravir (50 mg, once daily) was studied in 24 healthy volunteers. Sofosbuvir AUC and Cmax decreased by 8% and 92%, respectively. GS-331007 AUC and Ctau both decreased by 1% while Cmax increased by 1%. Velpatasvir AUC, Cmax, and Ctau decreased by 9%, 6%, and 12%, respectively. No dosage adjustments are required.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Mogalian E, Stamm L M, Osinusi A et al. Clin Infect Dis, 2018; 67(6): 934-940.